The University of Sydney | Sydney Eye Hospital

Research site
8 Macquarie Street, Sydney, New South Wales, Australia
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site


11 of 26
Status: Active
Trial type: Interventional
Funder type: Industry

A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

Study WR42221 is a Phase IIIb, global, multicenter, randomized, visual assessor-masked study designed to assess the efficacy, safety, and pharmacokin...

Neovascular Age-related Macular Degeneration (nAMD)
Device: Port Delivery System with Ranibizumab
Drug: Ranibizumab

This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled study evaluating the efficacy and safety of faricimab in pa...

Choroidal Neovascularization Secondary to Pathologic Myopia
Drug: Faricimab
Drug: Ranibizumab
Locations recently updated

The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous satralizumab, a recombinant, huma...

Thyroid Eye Disease
Drug: Satralizumab
Other: Placebo

This main long-term extension study is designed to evaluate the long-term safety and tolerability of faricimab 6 milligrams (mg) administered by intr...

Active, not recruiting
Neovascular Age-related Macular Degeneration
Other: Sham Procedure
Drug: Faricimab

Researchers are looking for a better way to treat people who have macular edema secondary to retinal vein occlusion (RVO).In people with RVO, a blood...

Macular Edema Secondary to Retinal Vein Occlusion
Drug: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose
Diagnostic Test: Fluorescein

Evaluate the effect of IONIS-FB-LRx on the rate of change of the area of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)...

Active, not recruiting
Macular Degeneration
Geographic Atrophy
Drug: Placebo

Acute adenoviral conjunctivitis is a highly contagious, widespread endemic disease associated with frequent outbreaks, significant patient discomfort...

Active, not recruiting
Adenoviral Conjunctivitis
Drug: OKG-0301

This trial is a phase II, multi-center, single-masked (assessors) dose-ranging study designed to evaluate the comparative safety and preliminary effi...

Active, not recruiting
Diabetic Macular Oedema
Retinal Vein Occlusion With Macular Oedema
Drug: IBE-814 70ug
Drug: IBE-814 140ug

The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with DME.

Diabetic Macular Edema (DME)
Drug: KHK4951
Drug: Aflibercept Injection

The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.

Neovascular Age-Related Macular Degeneration (nAMD)
Drug: Aflibercept Injection
Drug: KHK4951

This study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.

Uveitic Macular Edema
Drug: Vamikibart
Other: Sham

Trial conditions

Edema (8 trials)
Macular Degeneration (8 trials)
Macular Edema (8 trials)
Wet Macular Degeneration (4 trials)
Atrophy (3 trials)
Geographic Atrophy (3 trials)
Diabetic Retinopathy (2 trials)
Eye Diseases (2 trials)
Neoplasm Metastasis (2 trials)
Retinal Diseases (2 trials)

And 22 more

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems